ARTICLE

PARK16 rs708730 Polymorphism Decreases Parkinson’s Disease Risk in European Ancestry Population: A Meta-analysis

Zhijie Han¹,² Baochu Wei¹,⁴ Chenghong Zhang¹,⁵ Hongtian Zhu¹,⁵ Lei Tang¹,⁵ Ruili Lin¹,⁵ Dian He¹,²,⁴ Yang Zhang¹,² Pingrong Yang¹,⁴ Junquan He¹,⁴ Pingshun Song¹,⁴

1. Materia Medica Development Group, Institute of Medicinal Chemistry, Lanzhou University School of Pharmacy, Lanzhou, 730000, China
2. Department of Bioinformatics, School of Basic Medicine, Chongqing Medical University, Chongqing, 400016, China
3. Lanzhou Pulmonary Hospital, Lanzhou, 730046, China
4. Gansu Institute for Drug Control, Lanzhou, 730070, China
5. Lanzhou Weihuan Biological Science and Technology Development Co., Ltd., Lanzhou, 730000, China

ARTICLE INFO

Article history
Received: 24 April 2019
Accepted: 23 April 2020
Published Online: 30 April 2020

Keywords:
Parkinson’s disease
Genome-wide association studies
Meta-analysis
PARK16 rs708730 polymorphism

ABSTRACT

Parkinson’s disease (PD) is a complex fatal chronic neurodegenerative disease most common in elderly people. The early genome-wide association studies (GWAS) found that the minor allele variant of PARK16 rs708730 polymorphism is a significant protective factor for PD in Caucasian populations. However, these results cannot be repeated by the following studies in Caucasian populations and other populations. We considered that the inconsistency of the findings may be caused by the small-scale samples or the heterogeneity among different populations. Therefore, in this study, we synthesized the previous related GWAS studies through three authoritative sources, and used the large-scale samples (10,645 PD cases and 30,499 controls) to reevaluate the association between rs708730 polymorphism and PD. The results showed that there is no association between them in Asian ancestry population. While, in European ancestry population, we found that the minor allele variant (G) of rs708730 polymorphism is significantly associated with a decreased risk of PD. Collectively, our findings further verified the association of rs708730 with PD and show its genetic heterogeneity among different populations, which can help to develop a better understanding of the PD’s pathogenesis.

*Corresponding Author:
Dian He,
Materia Medica Development Group, Institute of Medicinal Chemistry, Lanzhou University School of Pharmacy, Lanzhou, 730000, China;
Innovative Drug Research and Bioinformatics Group, School of Pharmaceutical Sciences, Chongqing University, Chongqing, 401331, China;
Email: hed@lzu.edu.cn;
Yang Zhang,
Materia Medica Development Group, Institute of Medicinal Chemistry, Lanzhou University School of Pharmacy, Lanzhou, 730000, China;
Innovative Drug Research and Bioinformatics Group, School of Pharmaceutical Sciences, Chongqing University, Chongqing, 401331, China;
Email: 20162901007@cqu.edu.cn
1. Introduction

Parkinson’s disease (PD) is a chronic progressive complex neurodegenerative disorder, and it is common in elderly people\(^1,2\). Particularly, the prevalence of PD in the people aged above 60 years is more than three times that in entire population\(^2\). Another study further showed a rising popularizing rate of PD with age (425 per 100,000 in individuals aged 60-69 years, 1087 in 70-79 years, and 1903 in aged above 80 years)\(^3\). PD is characterized by the dopaminergic neurons prominent death in substantia nigra and Lewy body formation\(^4,5\).

A previous study predicted that the newly diagnosed PD patients are expected to reach as many as 8.7-9.3 million by 2030 from 4.1-4.6 million in 2005 around the 15 most populous nations\(^6\).

The variants in a specific gene region, which is designated as PARK16 (1q32), are considered to play an important role in pathogenesis of PD\(^7\-9\). In this region, the single nucleotide polymorphism (SNP) rs708730 (G < A) was identified significantly associated with PD in Caucasian populations by a large-scale genome-wide association studies (GWAS)\(^10\). Particularly, Sanchez et al. collected and analyzed 14,075 Caucasian individuals (including 5,272 PD patients and 8,803 controls) from USA, Germany and UK by GWAS. They found that the rs708730 polymorphism minor allele variant (G) can reduce the risks of PD (odds ratio \(OR = 0.90, P = 1.59 \times 10^{-3}\)\(^10\)).

However, the consistent and inconsistent results for the effect of rs708730 variant on PD in USA, UK, China, Japan and Korea populations have been reported by the subsequent studies. For example, by analyzing 2,000 PD and 1986 control Caucasian subjects from USA, Hamza et al. also found that the rs708730 polymorphism minor allele variant is a protective factor for PD \(OR = 0.87, P = 0.03\)\(^11\). While according to the results of two independent studies, the rs708730 is found not associated with PD in UK \(OR = 0.98, P = 0.82\)\(^12\) and China populations \(OR = 0.81, P = 0.19\)\(^13\), respectively. Further, Satake et al. and Chung et al. selected 20,392 (including 2,011 PD patients and 18,381 controls) and 2,244 (including 1,036 PD patients and 1,208 controls) individuals from Japan and Korea, respectively, and they found that the minor allele of rs708730 are associated with an increased risk of PD \(OR = 1.33\) and \(P = 2.43 \times 10^{-8}\) for Japan population\(^14\); \(OR = 1.22\) and \(P = 0.008\) for Korea population\(^15\).

We considered that the inconsistency of the findings may be caused by the small-scale samples or the heterogeneity among different populations. To overcome these defects and enhance reliability of the results, we selected a more complete sample set by searching the PubMed, ClinicalKey and Google Scholar databases. The large-scale samples include 10,645 PD patients and 30,499 controls from nine related GWAS studies, which are involved in European and Asian ancestry populations. Then, according to the method used in the previous studies\(^16-29\), we conducted a meta-analysis to reevaluated the association between rs708730 polymorphism and PD. Further, we explored the heterogeneity among different populations and assessed the association between rs708730 and PD in Asian and European ancestry populations, respectively.

2. Methods

2.1 Literatures Acquisition and Studies Selection

We selected all the possible studies by searching PubMed (http://www.ncbi.nlm.nih.gov/pubmed) and ClinicalKey (https://www.clinicalkey.com/) databases, respectively, using the keywords: “Parkinson’s disease” and “rs708730”, or “Parkinson’s disease” and “PARK16”. We collected all these literatures from the two databases before the last update on September 25 2018. And then, the Google Scholar (http://scholar.google.com/) was further used to query all the references of the studies and the articles citing these studies identified from PubMed and ClinicalKey databases.

After that, the appropriate studies were identified according to the following criteria: (1) The study is designed according to the case-control strategy. (2) The study evaluates the association of rs708730 polymorphism and PD. (3) The study provides the number of cases and controls. (4) The ethnicity of each individual in the study was presented clearly. (5) The number of rs708730 genotypes both in cases and controls are provided by the study or it provides enough data to calculate these. (6) The \(OR\) value with 95% confidence interval (CI) and the \(P\) value are provided by the study or it provides enough data to calculate these.

2.2 Data Extraction

The following information from each of the selected studies was extracted: (1) The publication year and the first author of these studies. (2) The ethnicity and population of the participants in these studies. (3) The number of PD patients and healthy controls in these studies. (4) The genotype information of rs708730 both in the PD patients and healthy controls. (5) The association analysis results \((OR\) value with 95%CI and \(P\) value) in these studies. (6) The genotyping platforms. For the genotypes, \(OR\) value
and the 95%CI as well as the corresponding P value, we worked them out using R program (http://www.r-project.org/) if these informations didn’t be provided directly.

### 2.3 Genetic Model Choice

Among the two alleles G and A of the rs708730 polymorphism, G was the minor allele. According to the previous studies [25-29], the allele model (A allele versus G allele), the dominant model (AG+GG versus AA), the recessive model (GG versus AA+AG), and the additive model (AA versus GG) are the common genetic model for the association analysis. Given that only the genotyping data of A allele versus G allele are provided from the selected studies (shown in Table 1), the allele model was used to analyze the association between rs708730 polymorphism and PD in this study.

### 2.4 Heterogeneity Test

We chose the two common quantities, Cochran’s $Q$ and $I^2$, to measure the heterogeneity among the different ethnic groups in this study. Cochran’s $Q$ approximately follows a chi-squared distribution whose degrees of freedom is $k-1$ (where $k$ is the number of studies), and the $I^2$ value is calculated through Cochran’s $Q$:

$$I^2 = \frac{Q - (k - 1)}{Q} \times 100\%$$

which ranges from 0 to 100%. Usually, the low, moderate, high and extreme heterogeneity are tentatively assigned to the $I^2$ value of <25%, 25-50%, 50-75% and >75%, respectively. According to previous studies, when the $I^2$>50% and $P$<0.01, the heterogeneity among different ethnic groups is deemed significant in this study [25-29].

### 2.5 Meta-analysis and Subgroup Analysis

Usually, there are two models (fixed effect model and random effect model) used for meta-analysis. According to the results of heterogeneity test, we used the random and the fixed effect model in the meta-analysis when heterogeneity is significant or not, respectively [30]. In meta-analysis, we calculated the pooled OR value and its 95%CI as well as the corresponding P value to measure the association between the rs708730 polymorphism and PD based on the Z test. The meta-analysis was performed by the R package ‘meta’ (http://cran.r-project.org/web/packages/meta/index.html). By most criteria, the threshold of significant association was set as 95%CI of OR value do not include 1 and. And then, we further split the original samples into European and Asian ancestry populations, and performed the meta-analyses in each subgroup, respectively.

### 2.6 The Sensitivity and Publication Bias Analysis

By most criteria, we used the two methods, Begg’s test [60] and Egger’s test [61], to evaluate the publication bias in this allele model. When the $P$ values are less than 0.05, we deemed the publication bias is significant. Then, the funnel plot was drawn to show the results of the publication bias analysis based on its asymmetry. Finally, we performed the sensitivity analyses. For this purpose, each of the selected studies was excluded from the whole sample orderly to assess the influence of these studies one by one.

### 3. Results

#### 3.1 Study Collection and Data Acquisition

Through the keyword search in PubMed and ClinicalKey databases and the filtration according to these criteria (see Methods for details), we identified a total 5 articles and corresponding 9 studies in them which include 10,645 PD cases and 30,499 controls from European and Asian ancestry populations. Moreover, another related study involved in Asian ancestry population was further obtained by checking the citation using Google Scholar. The workflow was shown in Figure 1. Then, we extracted the characteristics of these 9 studies, and the main contents were exhibited in Table 1. Finally, we counted the rs708730 polymorphism genotype data of each study for the following meta-analysis (Table 2).

**Figure 1.** The flow chart of studies selection for re-evaluating the association of SNP rs708730 with PD

![Figure 1](https://doi.org/10.30564/jgm.v1i2.798)
3.2 Heterogeneity Test

Given that only the genotyping data of G and A allele are provided from the 9 studies, we first tested the heterogeneity of all these samples based on the allele model. We found a significant genetic heterogeneity of rs708730 polymorphism among these selected samples ($I^2=83\%$ and $P<0.01$). Therefore, according to the ethnicity of these samples, we further tested the rs708730 polymorphism heterogeneity in European and Asian ancestry populations, respectively. We also found a significant genetic heterogeneity of rs708730 polymorphism among Asian ancestry populations ($I^2=90\%$ and $P<0.01$). However, we did not identify the significant genetic heterogeneity among the European ancestry populations ($I^2=0$ and $P=0.63$).

3.3 Meta-analysis and Subgroup Analysis

Because we observed a significant heterogeneity for all these samples, we performed a meta-analysis to assess the association between rs708730 polymorphism and PD using the random effect model. We have not found a significant association for the comprehensive population based on the allele model ($OR=0.989$, $95\% CI=0.878-1.115$, $P=0.875$). The corresponding forest plot was described in Figure 2. Given that the genetic heterogeneity of rs708730 polymorphism in the comprehensive population is significant, we further divided these samples into Asian and European ethnicity subgroups. According to the results of heterogeneity, we performed the meta-analyses using the fixed effect and random effect model for the European and Asian ancestry populations, respectively. Still, we have not observed a significant association between rs708730 polymorphism and PD in the Asian ancestry population ($OR=1.055$, $95\% CI=0.811-1.372$, $P=0.689$) (Figure 3a). However, the significant association was identified in the European ethnicity subgroups. Particularly, we found that the minor allele G of rs708730 polymorphism is significantly associated with a reduced risk of PD in European ancestry population subgroups.

### Table 1. The main contents in the selected studies for this meta-analysis

| Study                | Year      | Country            | Ethnicity | No. of cases | No. of controls | Genotyping platform | Kind of genotype |
|----------------------|-----------|--------------------|-----------|--------------|------------------|---------------------|------------------|
| Sanchez et al. (Stage I) | 2009      | USA and Germany    | European  | 1,063        | 3,071            | HumanHap550         | G/A              |
| Sanchez et al. (Stage II) | 2009     | USA, UK and Germany | European | 3,452        | 4,756            | Illumina            | G/A              |
| Pankratz et al.       | 2009      | UK                 | European  | 857          | 867              | Illumina            | G/A              |
| Hamza et al.          | 2010      | USA                | European  | 2,000        | 1,986            | Illumina            | G/A              |
| Yan et al.            | 2011      | China              | Asian     | 226          | 230              | ABI 3100 automated sequencer | G/A |
| Satake et al. (Stage I) | 2009      | Japan              | Asian     | 1,078        | 2,628            | Illumina            | G/A              |
| Satake et al. (Stage II) | 2009     | Japan              | Asian     | 612          | 14,139           | VeraCode            | G/A              |
| Satake et al. (Stage III) | 2009     | Japan              | Asian     | 321          | 1,614            | TaqMan              | G/A              |
| Chung et al.          | 2013      | Korea              | Asian     | 1,036        | 1,208            | Illumina            | G/A              |
| All                  |           |                    |           | 10,645       | 30,499           |                     |                  |

Note: “G/A” means that the data of genotypes G and A are provided by the study both in cases and controls.

### Table 2. The genotype information of the selected studies

| Study                | Year      | Ethnicity | Minor allele | MAF in case/control | PD.G | TOTAL.G | PD.A | TOTAL.A |
|----------------------|-----------|-----------|--------------|---------------------|------|---------|------|---------|
| Sanchez et al. (Stage I) | 2009      | European  | G            | 0.15/0.17           | 319  | 1363    | 1807 | 6905    |
| Sanchez et al. (Stage II) | 2009     | European  | G            | 0.16/0.17           | 1105 | 2722    | 5799 | 13694   |
| Pankratz et al.       | 2009      | European  | G            | 0.17/0.17           | 291  | 586     | 1423 | 2862    |
| Hamza et al.          | 2010      | European  | G            | 0.16/0.17           | 640  | 1315    | 3360 | 6657    |
| Yan et al.            | 2011      | Asian     | G            | 0.19/0.23           | 87   | 192     | 365  | 720     |
| Satake et al. (Stage I) | 2009      | Asian     | G            | 0.14/0.18           | 302  | 1248    | 1854 | 6164    |
| Satake et al. (Stage II) | 2009     | Asian     | G            | 0.15/0.17           | 1040 | 25077   | 184  | 4991    |
| Satake et al. (Stage III) | 2009     | Asian     | G            | 0.12/0.18           | 565  | 3212    | 77   | 658     |
| Chung et al.          | 2013      | Asian     | G            | 0.19/0.22           | 1678 | 3563    | 394  | 925     |

Note: MAF: Minor allele frequency
3.4 The Sensitivity and Publication Bias Analysis

After the Egger’s test and Begg’s test, we found no significant publication bias in all these studies based on the allele model (Egger’s test, $P=0.393$, and Begg’s test, $P=0.404$). The results were described in a funnel plot (Figure 4). Moreover, we further excluded each study orderly to perform the sensitivity analysis. The results showed that the heterogeneity and the association between rs708730 polymorphism and PD have not changed significantly when excluding any of the studies from the whole. The detailed information was shown in the Table 3.

Note: Because the genetic heterogeneity of rs708730 polymorphism in the comprehensive population is significant, we used the random effect model to perform the meta-analysis of all 9 selected studies in the allele contrast (G versus A).
4. Discussion

PD is characterized by the Lewy body formation and dopaminergic neurons death in substantia nigra, and is most seen in elderly people [1-5]. The previous studies reported that a specific gene region, PARK16 (1q32), plays a key role in PD’s pathogenesis [7-9]. And then, the subsequent GWAS studies found that the SNP rs708730 is in PARK16 and its minor allele variant (G) is a protective factor for PD in Caucasian populations [10,11]. However, these results cannot be repeated in China (OR=0.81, P=0.19) [12], Japan (OR=1.33, P=2.43×10−8) [13], Korea (OR=1.22, P=0.008) [14] and another Caucasian population (OR=0.98, P=0.82) [15]. We considered that the inconsistency of the findings may be caused by the small-scale samples or the heterogeneity among different populations. Therefore, after selecting and summarizing the related studies, the larger scale samples and more comprehensive population were used to explore the association between rs708730 polymorphism and PD.

In this study, 9 related GWAS studies (involving in a total 10,645 PD cases and 30,499 controls from USA, UK, Germany, China, Japan, and Korea) were selected through three authoritative public databases. Then, we re-evaluated the association between rs708730 polymorphism and PD in European and Asian ancestry ethnicity, respectively. The results showed that there is no association between rs708730 polymorphism and PD in Asian ancestry population (OR=1.005, 95% CI=0.811−1.372 P=0.689). While, in European ancestry population, we found that the minor allele variant (G) of rs708730 polymorphism is significantly associated with a reduced risk of PD (OR=0.924, 95% CI=0.872−0.979 P=0.007). Moreover, we found that genetic heterogeneity of rs708730 polymorphism is significant on the whole (I²=83% and P<0.01). When we split the original samples into European and Asian ancestry populations, the genetic heterogeneity is still significant in Asian (I²=90% and P<0.01) but not European ancestry populations (I²=0 and P=0.63). So, the more similar association studies should be performed in more subgroups of Asian ancestry population.

To our knowledge, this meta-analysis selected the most comprehensive samples by far to explore the association between the PARK16 rs708730 polymorphism and PD. Our findings reveal a significant protective function of rs708730 minor allele variant for PD in European but not Asian ancestry populations, which have further verified the association between rs708730 and PD and also show its genetic heterogeneity among different populations. In summary, the findings of this study would help deepen cognition about pathogenesis of PD.

Acknowledgements

This work was supported by Lanzhou Science and Technology Bureau Program Funds (2017-RC-16, 2018-1-110), Gansu Science and Technology Fund Grant (ID: 17ZD2FA009) and National Science and Technology Ministry(ID: 2017ZX09101001).

References

[1] Kalia LV, Lang AE. Parkinson’s disease. Lancet, 2015, 386(9996): 896-912. DOI: 10.1016/S0140-6736(14)61393-3
[2] de Lau LM, Breteler MM. Epidemiology of Parkinson’s disease. The Lancet Neurology, 5 (6): 525-535. DOI: 10.1016/S1474-4422(06)70471-9
[3] Pringsheim T, Jette N, Frolkis A, Steeves TD. The prevalence of Parkinson’s disease: a systematic review and meta-analysis. Movement disorders : official journal of the Movement Disorder Society, 2014, 29(13): 1583-1590. DOI: 10.1002/mds.25945
[4] Braak H, Del Tredici K, Rub U, de Vos RA, Jansen Steur EN, Braak E. Staging of brain pathology related to sporadic Parkinson’s disease. Neurobiology of aging, 2003, 24 (2): 197-211.

Table 3. The result of Sensitivity Analysis in allele model

| The omitted study | Year | OR   | 95% CI        | p-value | tau^2 | I^2 |
|-------------------|------|------|---------------|---------|-------|-----|
| Sanchez et al. (Stage I) | 2009 | 1.0087 | [0.8824; 1.1531] | 0.8989  | 0.0292 | 84.00% |
| Sanchez et al. (Stage II) | 2009 | 1.0005 | [0.8624; 1.1608] | 0.9945  | 0.0373 | 84.70% |
| Pankratz et al. | 2009 | 0.9889 | [0.8659; 1.1294] | 0.8688  | 0.0292 | 84.80% |
| Hamza et al. | 2010 | 0.9993 | [0.8685; 1.1497] | 0.9921  | 0.0326 | 84.80% |
| Yan et al. | 2011 | 1.005 | [0.8865; 1.1393] | 0.9384  | 0.0267 | 84.50% |
| Satake et al. (Stage I) | 2009 | 1.0266 | [0.9152; 1.1515] | 0.6546  | 0.0198 | 78.20% |
| Satake et al. (Stage II) | 2009 | 0.9723 | [0.8553; 1.1053] | 0.6679  | 0.0265 | 83.20% |
| Satake et al. (Stage III) | 2009 | 0.9449 | [0.8516; 1.0484] | 0.2852  | 0.0161 | 76.40% |
| Chung et al. | 2013 | 0.9626 | [0.8530; 1.0863] | 0.5367  | 0.0227 | 80.60% |
[5] Lenka A, Padmakumar C, Pal PK. Treatment of Older Parkinson’s Disease. International review of neurobiology, 2017, 132: 381-405. DOI: 10.1016/bs.irn.2017.01.005

[6] Dorsey ER, Constantinescu R, Thompson JP, Biglan KM, Holloway RG, Kieburz K, Marshall FJ, Ravina BM, Schifitto G, Siderowf A, Tanner CM. Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030. Neurology, 2007, 68(5): 384-386. DOI: 10.1212/01.wnl.0000247740.47667.03

[7] Tan EK, Kwok HH, Tan LC, Zhao WT, Prakash KM, Au WL, Pavanni R, Ng YY, Satake W, Zhao Y, Toda T, Liu JJ. Analysis of GWAS-linked loci in Parkinson disease reaffirms PARK16 as a susceptibility locus. Neurology, 2010, 75 (6): 508-512. DOI: 10.1038/jhg.2015.34

[8] Pihlstrom L, Rengmark A, Bjornara KA, Dizdar N, Fardell C, Forsgren L, Holmberg B, Larsen JP, Linder J, Nissbrandt H, Tysnes OB, Dietrichs E, Toft M. Fine mapping and resequencing of the PARK16 locus in Parkinson’s disease. Journal of human genetics, 2015, 60 (7): 357-362. DOI: 10.1038/jhg.2015.34

[10] Simon-Sanchez J, Schulte C, Bras JM, Sharma M, Gibbs JR, Berg D, Paisan-Ruiz C, Lichtner P, Scholz SW, Hernandez DG, Kruger R, Fedoroff M, Klein C, Goate A, Perlmutter J, Bonin M, Nalls MA, Illig T, Gieger C, Houlden H, Steffens M, Okun MS, Toda T, Singleton AB, Gasser T. Genome-wide association study reveals genetic risk underlying Parkinson’s disease. Nature genetics, 2009, 41(12): 1308-1312. DOI: 10.1038/ng.485

[15] Chung SJ, Jung Y, Hong M, Kim MJ, You S, Kim YJ, Kim J, Song K. Alzheimer’s disease and Parkinson’s disease genome-wide association study top hits and risk of Parkinson’s disease in Korean population. Neurobiology of aging, 2013, 34(11): 2695 e2691-2697. DOI: 10.1016/j.neurobiolaging.2013.05.022

[16] G Chen, X Fu, G Wang, G Liu, X Bai. Genetic Variant rs10757278 on Chromosome 9p21 Contributes to Myocardial Infarction Susceptibility. International journal of molecular sciences, 2015, 16(5): 11678-11688. DOI: 10.3390/ijms160511678

[17] Y Li , D Song, Y Jiang, J Wang, R Feng, L Zhang, G Wang, Z Chen, R Wang, Q Jiang, G Liu. CR1 rs3818361 Polymorphism Contributes to Alzheimer’s Disease Susceptibility in Chinese Population. Molecular neurobiology, 2016, 53(6): 4054-4059. DOI: 10.1007/s12035-015-9343-7

[18] D He, L Ma, R Feng, L Zhang, Y Jiang, Y Zhang, G Liu. Analyzing large-scale samples highlights significant association between rs10411210 polymorphism and colorectal cancer. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2015, 74: 164-168. DOI: 10.1016/j.biopha.2015.08.023

[19] Y Yang, W Wang, L Zhang, S Zhang, G Liu, Y Yu, M Liao. Association of single nucleotide polymorphism rs6983267 with the risk of prostate cancer. Oncotar-
[20] G Liu, Y Xu, Y Jiang, L Zhang, R Feng, Q Jiang. PI-CALM rs3851179 Variant Confers Susceptibility to Alzheimer’s Disease in Chinese Population. Molecular neurobiology, 2017, 54(5): 3131-3136. DOI: 10.1007/s12035-016-9886-2

[21] P Han, G Liu, X Lu, M Cao, Y Yan, J Zou, X Li, G Wang. CDH1 rs9929218 variant at 16q22.1 contributes to colorectal cancer susceptibility. Oncotarget, 2016, 7(30): 47278-47286. DOI: 10.18632/oncotarget.9758

[22] Y Yang, W Wang, G Liu, Y Yu, M Liao. Association of single nucleotide polymorphism rs3803662 with the risk of breast cancer. Scientific reports, 2016, 6: 29008. DOI: 10.1038/srep29008

[23] Y Hu, L Zheng, L Cheng, Y Zhang, W Bai, W Zhou, T Wang, Z Han, J Zong, S Jin, J Zhang, G Liu, Q Jiang. GAB2 rs2373115 variant contributes to Alzheimer’s disease risk specifically in European population. Journal of the neurological sciences, 2017, 375: 18-22. DOI: 10.1016/j.jns.2017.01.030

[24] G Liu, JY Sun, M Xu, XY Yang, BL Sun. SORL1 Variants Show Different Association with Early-Onset and Late-Onset Alzheimer’s Disease Risk. Journal of Alzheimer’s disease : JAD, 2017, 58 (4): 1121-1128. DOI: 10.3233/JAD-170005

[25] G Liu, F Li, S Zhang, Y Jiang, G Ma, H Shang, J Liu, R Feng, L Zhang, M Liao, B Zhao, K Li. Analyzing large-scale samples confirms the association between the ABCA7 rs3764650 polymorphism and Alzheimer’s disease susceptibility. Molecular neurobiology, 2014, 50(3): 757-764. DOI: 10.1007/s12035-014-8670-4

[26] G Liu, H Wang, J Liu, J Li, H Li, G Ma, Y Jiang, Z Chen, B Zhao, K Li. The CLU gene rs11136000 variant is significantly associated with Alzheimer’s disease in Caucasian and Asian populations. Neuro-molecular medicine, 2014, 16 (1): 52-60. DOI: 10.1007/s12017-013-8250-1

[27] Z Han, Q Jiang, T Zhang, X Wu, R Ma, J Wang, Y Bai, R Wang, R Tan, Y Wang. Analyzing large-scale samples confirms the association between the rs1051730 polymorphism and lung cancer susceptibility. Scientific reports, 2015, 5: 15642. DOI: 10.1038/srep15642

[28] M Liao, G Wang, B Quan, X Qi, Z Yu, R Feng, L Zhang, Y Jiang, Y Zhang, G Liu. Analyzing large-scale samples confirms the association between rs16892766 polymorphism and colorectal cancer susceptibility. Scientific reports, 2015, 5: 7957. DOI: 10.1038/srep07957

[29] Z Han, J Qu, J Zhao, X Zou. Analyzing 74,248 Samples Confirms the Association Between CLU rs11136000 Polymorphism and Alzheimer’s Disease in Caucasian But Not Chinese population. Scientific reports, 2018, 8(1): 11062. DOI: 10.1038/s41598-018-29450-2

[30] Demets DL. Methods for combining randomized clinical trials: strengths and limitations. Statistics in medicine, 1987, 6 (3): 341-350.